DE602006016621D1 - Olanzapin enthaltende pharmazeutische zusammensetzung - Google Patents

Olanzapin enthaltende pharmazeutische zusammensetzung

Info

Publication number
DE602006016621D1
DE602006016621D1 DE602006016621T DE602006016621T DE602006016621D1 DE 602006016621 D1 DE602006016621 D1 DE 602006016621D1 DE 602006016621 T DE602006016621 T DE 602006016621T DE 602006016621 T DE602006016621 T DE 602006016621T DE 602006016621 D1 DE602006016621 D1 DE 602006016621D1
Authority
DE
Germany
Prior art keywords
olanzapine
pharmaceutical composition
containing pharmaceutical
composition
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006016621T
Other languages
English (en)
Inventor
Torfi Kristjansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Group PTC ehf
Original Assignee
Actavis Group PTC ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35516297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006016621(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actavis Group PTC ehf filed Critical Actavis Group PTC ehf
Publication of DE602006016621D1 publication Critical patent/DE602006016621D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE602006016621T 2005-11-03 2006-10-27 Olanzapin enthaltende pharmazeutische zusammensetzung Active DE602006016621D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0522474.6A GB0522474D0 (en) 2005-11-03 2005-11-03 A pharmaceutical formulation
PCT/IB2006/003922 WO2007052164A2 (en) 2005-11-03 2006-10-27 A pharmaceutical formulation containing olanzapine

Publications (1)

Publication Number Publication Date
DE602006016621D1 true DE602006016621D1 (de) 2010-10-14

Family

ID=35516297

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006016621T Active DE602006016621D1 (de) 2005-11-03 2006-10-27 Olanzapin enthaltende pharmazeutische zusammensetzung

Country Status (8)

Country Link
EP (1) EP1928428B1 (de)
CN (1) CN101309673A (de)
AT (1) ATE479428T1 (de)
CA (1) CA2626585A1 (de)
DE (1) DE602006016621D1 (de)
ES (1) ES2350121T3 (de)
GB (1) GB0522474D0 (de)
WO (1) WO2007052164A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
CN104208031B (zh) * 2013-07-01 2016-08-31 成都苑东生物制药股份有限公司 一种奥氮平片组合物及其制备方法
SI2774606T1 (sl) 2014-02-14 2019-05-31 Synthon B.V. Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
SI21303A (sl) * 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
EP1583519A1 (de) * 2002-12-20 2005-10-12 St. James Associates Llc/Faber Research Series Hochdruck-tablettierung für arzneimittelformulierungen
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine

Also Published As

Publication number Publication date
GB0522474D0 (en) 2005-12-14
EP1928428B1 (de) 2010-09-01
ATE479428T1 (de) 2010-09-15
EP1928428A2 (de) 2008-06-11
WO2007052164A2 (en) 2007-05-10
WO2007052164A8 (en) 2008-04-17
WO2007052164A3 (en) 2007-08-09
ES2350121T3 (es) 2011-01-18
CA2626585A1 (en) 2007-05-10
CN101309673A (zh) 2008-11-19

Similar Documents

Publication Publication Date Title
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
EA201001083A1 (ru) Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
AR062000A1 (es) Formulaciones de modificador de respuesta inmune
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
BRPI0719395C1 (pt) tablete revestido de filme
ATE337793T1 (de) Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
ATE374016T1 (de) Tablette mit hohem wirkstoffgehalt
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
BRPI0507654A (pt) composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
BRPI0720684A2 (pt) composto, medicamento, composição farmacêutica que contém e uso do composto
ATE415949T1 (de) Pharmazeutische formulierung mit levothyroxin- natrium
IS2677B (is) Lyfjablanda sem felur í sér pýrimídín-A-ónafleiðu hjúpaða með sýrufjölliðu
ATE479428T1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
NO20073023L (no) Forhindring av vertikal endoparasitt infeksjoner
SV2006002238A (es) Inhibidores de la adenilato ciclasa soluble ref. p-sv-78. 959/gh
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
ATE489943T1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate